drugset / Trial / NCT03258320
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Phase 2/3
Recruiting
300 enrolled
Shanghai Jiao Tong University School of Medicine
Fudan University · collabQilu Hospital of Shandong University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
Timeline
- Start
- 2015-01
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 35 mg/m2 | Intravenous |
| Subject | Mitoxantrone | Small molecule | 4 mg/m2 | Intravenous |
| Subject | Satraplatin | Other / unclassified | 80 mg/m2 | Intravenous |